Menopause Management: Evaluation and Hormone Therapy Considerations

Menopause is a normal life transition, but its symptoms can significantly affect quality of life. A structured clinical evaluation helps licensed providers determine which patients may benefit from hormone therapy and which may be better served by other approaches.

Clinical Presentation

Menopause is diagnosed after 12 consecutive months without menses. The perimenopausal transition can begin several years earlier, with variable symptoms.

Common Symptoms:

• Vasomotor symptoms (hot flashes and night sweats)
• Sleep disruption
• Genitourinary symptoms, including vaginal dryness and dyspareunia
• Mood changes and cognitive complaints
• Menstrual irregularity during perimenopause

Evaluation

• Symptom history, menstrual history, and impact on function
• Personal and family history of breast cancer, venous thromboembolism, cardiovascular disease, and liver disease
• Blood pressure, BMI, and breast and pelvic examination as appropriate
• Laboratory testing when the diagnosis is unclear or to rule out other causes such as thyroid disease
• Age-appropriate screening, including mammography and bone density

Treatment Options

Menopausal hormone therapy is an established treatment for moderate to severe vasomotor symptoms and genitourinary syndrome of menopause. Guidance from professional societies generally supports individualized therapy using the lowest effective dose for the shortest duration needed to meet treatment goals, with periodic reassessment. Timing relative to menopause onset and the patient's age are important factors in the benefit-risk balance.

Considerations:

• Women with an intact uterus who use systemic estrogen require progestogen for endometrial protection
• Route of administration (oral, transdermal, vaginal, or pellet) may influence risk profile and patient preference
• Hormone therapy is not appropriate for every patient; contraindications must be reviewed
• Non-hormonal prescription options and lifestyle measures are alternatives for patients who cannot or prefer not to use hormones

Monitoring and Follow-Up

Patients should be reassessed for symptom response, side effects, and ongoing appropriateness of therapy. Routine screening and cardiovascular risk management continue regardless of treatment.

Provider Support Through Purepell

Providers who prescribe hormone therapy can work with Purepell through Halo Health Advisors. Evaluation, prescribing, and monitoring decisions remain with the licensed provider.